Zoledronic acid 5mg solution for infusion (Aclasta® ) contraindicated in patients with severe renal impairment with creatine clearance < 35mL/min

Novartis (Singapore) Pte Ltd issued a Dear Healthcare Professional Letter to inform healthcare professionals of important safety information regarding Aclasta® (zoledronic acid). From postmarketing surveillance, cases of acute renal failure requiring hospitalisation and/or dialysis or fatal outcome have been observed in patients with underlying moderate to severe renal impairment or with other risk factors. Hence, Aclasta® is now contraindicated in patients with severe renal impairment with creatinine clearance < 35 mL/min. Please refer to the Dear Healthcare Professional Letter for more details on the important considerations regarding renal adverse events associated with use of Aclasta®.
Healthcare professional
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.